Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01

Core Viewpoint - Hemostemix Inc. has appointed Dr. David B. Alper as the Multidisciplinary Physician Education Lead and a member of its Scientific Advisory Board, effective January 2026, to enhance physician education and clinical engagement initiatives related to its stem cell therapy, VesCell (ACP-01) [1][7]. Group 1: Appointment and Role of Dr. David B. Alper - Dr. Alper will lead physician-led education and clinical engagement initiatives, starting in Florida, focusing on wound-care podiatrists and limb-preservation teams [2]. - His role includes engaging with practitioners to promote the use of ACP-01 for treating pain and ischemia related to peripheral arterial disease and diabetic foot ulcers [2]. - Dr. Alper's extensive background includes leadership roles in various national organizations related to wound care and diabetes, enhancing his credibility in the field [5][6]. Group 2: Initiatives Under Dr. Alper's Leadership - The first initiative involves clinical practice engagement in Florida, where Dr. Alper will work with podiatry practitioners to increase the adoption of ACP-01 [2]. - The second initiative focuses on engaging Deans of Clinical Education at U.S. podiatry schools to introduce ACP-01 to new graduates and faculty [3]. - The third initiative supports participation in multidisciplinary educational forums, addressing ischemic disease and integrating ACP-01 into team-based practices [4]. Group 3: Company Overview and Product Information - Hemostemix is an autologous stem cell therapy company founded in 2003, recognized as a Technology Pioneer by the World Economic Forum [8]. - The company has developed and patented VesCell (ACP-01), which has shown significant clinical results, including a 0% mortality rate in a clinical trial for chronic limb threatening ischemia, compared to a 50% mortality rate in the general patient population [8]. - Hemostemix has completed seven clinical studies involving 318 subjects, with results published in eleven peer-reviewed journals, demonstrating the safety and efficacy of ACP-01 [8].